Type 1 Diabetes
Newly diagnosed type 1 diabetes in young diabetic patients (≤20 years) have rapid loss of insulin (measured by C-peptide).
In the 10 major pharma markets (US, major 5 in EU, Japan, China, India and Brazil) the prevalent diabetic population is approximately 190 million people of which 120 million are treated. The pharmaceutical market in 2012 was more than $ 28 billion with projected sales in 2022 of $68 billion.
After the diagnose T1D, the patient needs to do repeated daily blood sugar tests in order to verify that the blood glucose is within a narrow range of approximately 8.0-8.5 mmol/L.
Treatment of T1D patients normally follows the mutual recommended guidelines of American Diabetes Association (ADA) and the European Association for Study of Diabetes (EASD) and includes:
- Taking insulin
- Carbohydrate, fat and protein counting
- Frequent blood sugar monitoring
- Eating healthy foods
- Exercising regularly and maintaining a healthy weight
The goal is to keep the blood glucose level as close to normal values as possible and T1D patients need to continue a life-long administration of insulin.